At this moment in history, scientists, researchers, and innovative companies across the globe are working around the clock to develop a safe and effective treatment or vaccine for COVID-19. But as you likely know, it typically takes 10 to 15 years to develop a new drug therapy, conduct clinical trials, and pass regulatory requirements. What’s more, only 9.6% of the drugs that enter clinical trials are approved by the Food and Drug Administration. In short, drug developers are facing an uphill battle as they seek to accelerate product development and improve clinical outcomes.
If you've been following our blog for a while, you may have read our post on “Fail Fast” methodology, which focuses on spotting potential dead-ends early in the drug development cycle in order to reduce R&D costs, improve clinical outcomes, and speed time to market.
The fail fast methodology is particularly important for small and medium-sized enterprises (SMEs) in the biopharmaceutical market. Often, these companies do not have the resources to compete with big pharma and develop a successful drug on their own. Therefore, 'failing faster' and recognizing potential pitfalls early on - ahead of costly clinical trials - becomes ever more critical.
Want to take a deeper dive into this timely topic?
Join us for a complimentary webinar! Hosted by FierceBiotech, you'll hear from a panel of experts in biopharma discovery, R&D, and clinical trial design as they discuss the benefits and challenges of a fail fast strategy. Representatives from companies that have successfully adopted this innovative approach will participate as well, offering valuable insights on what worked—and what did not.
- When to implement 'fail fast' for maximum cost savings
- How to use 'fail fast' tactics to validate drug targets
- Where to shift your R&D strategies for optimal success
Reserve your spot now:
Fail Faster: How Biopharma Companies Can Capitalize on Early Drug Development Failures
Date: Friday, June 19th, 2020
Time: 11am ET / 8am PT
Duration: 1 hour